Astria Therapeutics (ATXS) Competitors

ANI Pharmaceuticals (NASDAQ:ANIP) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, community ranking, earnings, dividends, analyst recommendations, valuation and profitability.

Which has preferable valuation & earnings, ANIP or ATXS?

ANI Pharmaceuticals has higher revenue and earnings than Astria Therapeutics. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$614.38M	2.35	$18.78M	-$1.14	-58.18
Astria Therapeutics	N/A	N/A	-$72.89M	-$1.67	-3.74

Do insiders and institutionals have more ownership in ANIP or ATXS?

76.1% of ANI Pharmaceuticals shares are held by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are held by institutional investors. 12.7% of ANI Pharmaceuticals shares are held by company insiders. Comparatively, 2.9% of Astria Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community believe in ANIP or ATXS?

Astria Therapeutics received 133 more outperform votes than ANI Pharmaceuticals when rated by MarketBeat users. Likewise, 73.15% of users gave Astria Therapeutics an outperform vote while only 64.46% of users gave ANI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
ANI Pharmaceuticals	Outperform Votes 439 64.46%	Underperform Votes 242 35.54%
Astria Therapeutics	Outperform Votes 572 73.15%	Underperform Votes 210 26.85%

Is ANIP or ATXS more profitable?

Astria Therapeutics has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Astria Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	-1.28%	15.87%	6.88%
Astria Therapeutics	N/A	-43.58%	-29.36%

Do analysts prefer ANIP or ATXS?

ANI Pharmaceuticals currently has a consensus target price of $79.75, suggesting a potential upside of 20.23%. Astria Therapeutics has a consensus target price of $26.60, suggesting a potential upside of 325.60%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Astria Therapeutics is more favorable than ANI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00
Astria Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29

Which has more volatility & risk, ANIP or ATXS?

ANI Pharmaceuticals has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Does the media favor ANIP or ATXS?

In the previous week, ANI Pharmaceuticals had 6 more articles in the media than Astria Therapeutics. MarketBeat recorded 7 mentions for ANI Pharmaceuticals and 1 mentions for Astria Therapeutics. ANI Pharmaceuticals' average media sentiment score of 1.04 beat Astria Therapeutics' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ANI Pharmaceuticals	Positive
Astria Therapeutics	Neutral

Summary

ANI Pharmaceuticals and Astria Therapeutics tied by winning 9 of the 18 factors compared between the two stocks.